🏛️ Verified NIH Protocol • Sourced via U.S. National Library of Medicine (Last Synced: 2026-07-20)

Study of AUBE00 in Patients With Solid Tumors

🟢 Recruiting Phase 1 💊 Investigational Drug / Biologic Sponsor: Chugai Pharmaceutical

🩺 Protocol Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.

Primary Research Facility: South Texas Accelerated Research Therapeutics (START) Midwest (Grand Rapids, Michigan)

📋 Basic Study Criteria & Logistics Checklist

0 of 3 Checked

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Solid Tumors?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged 18 Years or older?

🔍 Protocol Specified Minimum Age: 18 Years

Able to attend required in-person clinic visits and study procedures at one of the participating study centers?

🔍 Logistical Requirement: 4 Registered Participating Sites

📍 Primary Site Map

Site: South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan

📍 All Participating Trial Locations (4 Sites)

Multi-Center Trial

This protocol is enrolling participants across multiple clinical centers:

1. South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan

2. The University of Texas MD Anderson Cancer Center — Houston, Texas

3. National Cancer Center Hospital East — Kashiwa, Chiba

4. National Cancer Center Hospital — Chuo-ku, Tokyo

📄 Print Doctor Discussion Sheet

Preview and print a 1-page summary with 5 tailored questions for your physician.

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.

🏛️ Official Government Provenance

NIH ClinicalTrials.gov Protocol Record

NCT Identifier: NCT07030959 • Last Synced: 2026-07-20

View on ClinicalTrials.gov ↗